Another Milestone in Overseas Strategy! Glatiramer Acetate Officially Shipped to Global Markets
On June 16, 2026, Hybio Pharmaceutical Co., Ltd. (hereinafter referred to as “Hybio”) achieved another major substantive breakthrough in its overseas commercial expansion: the company’s self-developed Glatiramer Acetate Injection has successfully completed all factory-release inspections and preparatory procedures, with finished products now fully loaded and shipped to the United States. This marks that, following the U.S. marketing authorization, the product has established a complete end-to-end chain from manufacturing to cross-border delivery, officially entering the stage of overseas commercial supply and terminal sales.
Following Liraglutide Injection, Glatiramer Acetate Injection is the second self-developed formulation product by Hybio to achieve commercial launch and sales in the U.S. market. The smooth shipment of this commercial batch not only represents a key milestone in monetizing the company’s R&D outcomes overseas but also fully validates its global peptide supply chain system and cross-border order fulfillment capabilities. Once the products arrive in the U.S. and are distributed through local channels, they will further broaden the company’s overseas market footprint, providing sustained support for long-term revenue growth and industry competitiveness.
The core product shipped to the U.S.—Glatiramer Acetate Injection (specification: 20mg/mL; 40 mg/mL)—is a synthetic peptide immunomodulator with high technological barriers, primarily indicated for relapsing forms of multiple sclerosis (MS). By mimicking the structure of myelin basic protein, it precisely modulates abnormal autoimmune responses, thereby effectively reducing attacks on the central nervous system myelin sheath. In clinical practice, it not only significantly lowers relapse frequency but also delays disease progression, offering a high-quality new treatment option for patients with clinically isolated syndrome and relapsing-remitting MS.
From the moment the product received U.S. marketing authorization to this successful cross-border shipment of the commercial batch, Hybio will continue to rely on its full-process, high-standard quality control system to ensure stable and continuous supply of the drug in overseas markets, while collaborating closely with international partners to advance market promotion and sales efforts. Looking ahead, the company will remain dedicated to the peptide drug field, driven by innovation and an internationalization strategy, accelerating the introduction of more high-quality formulations to the global stage.